Zimmer Biomet (ZBH) Tuesday said it received CE Mark approval for its RibFix Advantage intrathoracic fixation system, allowing sales in the European Economic Area and other markets recognizing the designation.
The system is designed to stabilize and fuse rib fractures using a minimally invasive approach compared to traditional surgical techniques. It adapts to the rib's anatomy during tightening to help reduce the fracture, according to the company.
Zimmer Biomet said this is the first CE Mark approval for an intrathoracic rib fixation system.
Price: 112.32, Change: -0.86, Percent Change: -0.76
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.